Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome

Lydic, Michael; McNurlan, Margaret A.; Bembo, Shirley A.; Mitchell, Lina; Komaroff, Eugene; Gelato, Marie C.

doi:10.1016/j.fertnstert.2005.11.069

Cited by 38 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 10-mg dose of ezetimibe is the standard adult daily dose, while the recommended starting dose of sevelamer hydrochloride is 800 mg with each meal. Since chromium picolinate is an over-the-counter preparation, there is no uniformity of dosing; however, a dose of 1000 mg daily has been utilized in published studies that evaluated its use in the treatment of diabetes mellitus and insulin resistance (9,10). The order of administration of the three test drugs was randomly varied among the subjects.…”

Section: Methodsmentioning

confidence: 99%

New Medications Which Decrease Levothyroxine Absorption

John-Kalarickal

Pearlman

Carlson

2007

Thyroid

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

New Medications Which Decrease Levothyroxine Absorption

John-Kalarickal

Pearlman

Carlson

2007

Thyroid

View full text Add to dashboard Cite

show abstract

“…Another review involving a total of 1690 subjects suggested that 13 out of 15 studies (including 11 randomized, controlled studies) reported significant improvement in at least one outcome of glycemic control [20]. Other reports suggest that chromium may have more consistent effects in certain clinical states and conditions such as insulin resistance or poorer glycemic control [20][21][22][23][24][25][26].…”

Section: Chromium Supplementation In Humans: Review Of Clinical Trialsmentioning

confidence: 99%

Current Concepts About Chromium Supplementation in Type 2 Diabetes and Insulin Resistance

2010

View full text Add to dashboard Cite

Chromium has been established to be an essential trace element in mammals in regard to maintenance of normal carbohydrate metabolism. Studies that provided chromium to human subjects in documented deficiency states noted improved glucose levels. However, controversy exists as to whether dietary supplementation with chromium should be routinely recommended in subjects without documented deficiencies. Over the recent past, several well-designed clinical trials have provided evidence in favor of and against a beneficial effect of chromium. It appears that across all subject phenotypes (eg, lean and obese, insulin sensitive and insulin resistant), a consistent significant and beneficial effect of chromium may not be observed. Specifically, recent data fail to demonstrate significant improvement in carbohydrate metabolism in individuals with metabolic syndrome, impaired glucose tolerance, or consistently in individuals with type 2 diabetes. However, patient selection may be an important factor in determining clinical response, as it was concluded that a clinical response to chromium (ie, decreased glucose and improved insulin sensitivity) may be more likely in insulin-resistant individuals with type 2 diabetes who have more elevated fasting glucose and hemoglobin A(1c) levels.

show abstract

“…Most of these data have been produced by clinical trials evaluating outcomes of nutritional supplementation [30][31][32][33][34][35][36]. A synthesis of the evidence produced by case-control studies is not available.…”

Section: Introductionmentioning

confidence: 99%

Blood Trace Element Concentrations in Polycystic Ovary Syndrome: Systematic Review and Meta-analysis

Spritzer

Lecke

Fabris

et al. 2016

Biol Trace Elem Res

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a prevalent condition in women of reproductive age. PCOS is characterized by androgen excess and chronic anovulation and associated with low-grade inflammation and metabolic comorbidities. Some trace elements have been linked to pathophysiological mechanisms of oxidative stress and inflammation in different disorders. Therefore, we conducted a systematic review and meta-analysis of the available evidence regarding trace element concentrations in PCOS. We reviewed MEDLINE and EMBASE in search of case-control, cross-sectional, and cohort studies published until September 2015. Of 183 studies identified, six were selected for systematic review. All used the Rotterdam criteria for the diagnosis of PCOS. Two studies evaluating chromium and one assessing cobalt levels did not observe differences between PCOS and controls. Another study recorded similar nickel and vanadium levels between the groups, but lower selenium concentrations in women with PCOS compared to controls. Four studies were included in the random effects model meta-analysis, for a total of 264 PCOS and 151 control women. Copper levels were found to be higher in women with PCOS than in controls [mean difference 0.12 ppm (95 % CI 0.07; 0.17 ppm); I 2 = 0 %]. Manganese [mean difference 0.04 ppm (95 % CI −0.05; 0.13 ppm); I 2 = 94.4 %] and zinc concentrations [mean difference 0.02 ppm (95 % CI −0.12; 0.16 ppm); I 2 = 92.4 %] were similar between the groups. The present results suggest a relationship between increased copper concentration and PCOS. This systematic review and meta-analysis is registered in PROSPERO under number CRD42016034036.

show abstract

Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome

Cited by 38 publications

References 39 publications

New Medications Which Decrease Levothyroxine Absorption

New Medications Which Decrease Levothyroxine Absorption

Current Concepts About Chromium Supplementation in Type 2 Diabetes and Insulin Resistance

Blood Trace Element Concentrations in Polycystic Ovary Syndrome: Systematic Review and Meta-analysis

Contact Info

Product

Resources

About